The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting illness, coronavirus disease 2019 (COVID-19), developed in Wuhan, China, in late 2019.1 Within months, COVID-19 became a worldwide pandemic, with millions of cases reported.2 Nephrologists have been front and center, caring for infected dialysis patients while also treating hospitalized patients with COVID-19 and acute kidney injury (AKI). A controversial aspect of therapy in both settings has been the use of erythropoiesis-stimulating agents (ESAs) to treat anemia experienced by patients with COVID-19.